Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen

被引：0

作者：

Seung-Hoon Beom

Jong Gwang Kim

Seung Hyuk Baik

Seong Hoon Shin

Inkeun Park

Young Suk Park

Myung-Ah Lee

Soohyeon Lee

So-Yeon Jeon

Sae-Won Han

Myoung Hee Kang

Jisu Oh

Jin Soo Kim

Jin Young Kim

Mi Sun Ahn

Dae Young Zang

Byung-Noe Bae

Hong Jae Jo

Hee Kyung Kim

Jung-Han Kim

Ji Ae Yoon

Dong Han Kim

机构：

[1] Yonsei University College of Medicine,Division of Medical Oncology, Department of Internal Medicine

[2] Kyungpook National University Chilgok Hospital,Department of Oncology/Hematology

[3] School of Medicine,Section of Colon and Rectal Surgery, Department of Surgery

[4] Kyungpook National University,Department of Internal Medicine

[5] Yonsei University College of Medicine,Division of Hematology

[6] Gangnam Severance Hospital,Oncology, Department of Internal Medicine

[7] Kosin University Gospel Hospital,Division of Hematology/Oncology, Department of Medicine

[8] Gachon University Gil Medical Center,Division of Medical Oncology, Department of Internal Medicine

[9] Samsung Medical Center,Division of Oncology/Hematology, Department of Internal Medicine

[10] Sungkyunkwan University School of Medicine,Department of Internal Medicine

[11] Cancer Research Institute,Department of Internal Medicine

[12] Seoul St. Mary’s Hospital,Division of Hematology

[13] College of Medicine,Oncology, Department of Internal Medicine

[14] The Catholic University of Korea,Division of Medical Oncology, Department of Internal Medicine

[15] Korea University Anam Hospital,Department of Surgery

[16] Jeonbuk National University Medical School,Division of Hematology and Oncology, Department of Internal Medicine

[17] Seoul National University Hospital and Seoul National University Cancer Research Institute,Department of Hematology

[18] Gyeongsang National University Changwon Hospital,Oncology

[19] Gyeongsang National University College of Medicine,Department of Internal Medicine

[20] Yongin Severance Hospital,Department of Surgery

[21] Chungnam National University College of Medicine,Department of Surgery

[22] Chungnam National University Sejong Hospital,Division of Oncology, Department of Internal Medicine

[23] Keimyung University Dongsan Hospital,Department of Internal Medicine

[24] Ajou University School of Medicine,undefined

[25] Hallym University Medical Center,undefined

[26] Hallym University College of Medicine,undefined

[27] Inje University Sanggye Paik Hospital,undefined

[28] Inje University College of Medicine,undefined

[29] Pusan National University School of Medicine,undefined

[30] Pusan National University Hospital,undefined

[31] Chungbuk National University Hospital,undefined

[32] Chungbuk National University College of Medicine,undefined

[33] Kangnam Sacred-Heart Hospital,undefined

[34] Hallym University College of Medicine,undefined

[35] Medical Affairs of Oncology,undefined

[36] GSK Korea,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Acquired resistance; Anti-VEGF agents; Chemotherapy; Colorectal cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1131 / 1143

页数：12

共 50 条

[31] Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
Hamaguchi, Tetsuya
Denda, Tadamichi
Kudo, Toshihiro
Sugimoto, Naotoshi
Ura, Takashi
Yamazaki, Kentaro
Fujii, Hirofumi
Kajiwara, Takeshi
Nakajima, Takako Eguchi
Takahashi, Shin
Otsu, Satoshi
Komatsu, Yoshito
Nagashima, Fumio
Moriwaki, Toshikazu
Esaki, Taito
Sato, Takeo
Itabashi, Michio
Oki, Eiji
Sasaki, Toru
Chiron, Marielle
Yoshino, Takayuki
[J]. CANCER SCIENCE, 2019, 110 (11) : 3565 - 3572
[32] Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
Watanabe, Jun
Terazawa, Tetsuji
Yamane, Shiho
Kazama, Hirotaka
Uetake, Hiroyuki
Yoshino, Takayuki
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (01) : 130 - 138
[33] Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer
Tomao, S., Sr.
Spinelli, G.
Rossi, L.
Pasciuti, G.
Arcangeli, G.
D'Aprile, M.
Veltri, E.
Baiano, G.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[34] Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
Jun Watanabe
Tetsuji Terazawa
Shiho Yamane
Hirotaka Kazama
Hiroyuki Uetake
Takayuki Yoshino
[J]. International Journal of Clinical Oncology, 2023, 28 : 130 - 138
[35] Phase II study of oral S-1 monotherapy in metastatic colorectal cancer after failure of both irinotecan and oxaliplatin-containing regimen.
Cho, B.
Choi, H.
Jeung, H.
Rha, S.
Ahn, J.
Roh, J.
Kim, Y.
Chung, H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 170S - 170S
[36] Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer
Chong, Dawn Q.
Manalo, Mary
Imperial, Marlowe
Teo, Patrick
Yong, Grace
Ng, Matthew
Tan, Iain B. H.
Choo, Su Pin
Chua, Clarinda
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (03) : 275 - 283
[37] Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
Yan, Qiong
Huang, Yuanyuan
Jian, Zhimin
Wang, Huizhong
Li, Weiyu
Zhang, Bei
Xie, Derong
[J]. ONCOTARGETS AND THERAPY, 2018, 11 : 2467 - 2473
[38] Combination of irinotecan, oxaliplatin and 5-fluorouracil as a rechallenge regimen for heavily pretreated metastatic colorectal cancer patients
Fernandes G.D.S.
Braghiroli M.I.
Artioli M.
Paterlini A.C.C.R.
Teixeira M.C.
Gumz B.P.
Girardi D.M.
Braghiroli O.F.M.
Costa F.P.
Hoff P.M.
[J]. Journal of Gastrointestinal Cancer, 2018, 49 (4) : 470 - 475
[39] Efficacy of chemotherapy in patients with unresectable or metastatic pancreatic acinar cell carcinoma: Potentially improved efficacy with oxaliplatin-containing regimen
Cheon, J.
Yoo, C.
Kim, B.
Kim, K-P.
Lee, J-L.
Kim, T. W.
Ryoo, B-Y.
Chang, H-M.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[40] Coi regimen (capecitabine, oxaliplatin, irinotecan) as front-line combination in metastatic colorectal cancer patients (PTS)
Ferrario, E.
Di Bartolomeo, M.
Buzzoni, R.
Del Vecchio, M.
Beretta, E.
Di Marco, R.
Paleari, D.
Gevorgyan, A.
Bajetta, E.
[J]. ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41

← 1 2 3 4 5 →